HomeCompareTQGEX vs JNJ

TQGEX vs JNJ: Dividend Comparison 2026

TQGEX yields 2.20% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TQGEX wins by $2.9K in total portfolio value
10 years
TQGEX
TQGEX
● Live price
2.20%
Share price
$20.35
Annual div
$0.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$253.74
Full TQGEX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TQGEX vs JNJ

📍 TQGEX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTQGEXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TQGEX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TQGEX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TQGEX
Annual income on $10K today (after 15% tax)
$187.08/yr
After 10yr DRIP, annual income (after tax)
$215.68/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $487.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TQGEX + JNJ for your $10,000?

TQGEX: 50%JNJ: 50%
100% JNJ50/50100% TQGEX
Portfolio after 10yr
$21.5K
Annual income
$540.76/yr
Blended yield
2.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TQGEX
No analyst data
Altman Z
0.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TQGEX buys
0
JNJ buys
0
No recent congressional trades found for TQGEX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTQGEXJNJ
Forward yield2.20%3.36%
Annual dividend / share$0.45$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$22.9K$20.0K
Annual income after 10y$253.74$827.78
Total dividends collected$2.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TQGEX vs JNJ ($10,000, DRIP)

YearTQGEX PortfolioTQGEX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,920$220.10$10,676$355.77+$244.00TQGEX
2$11,909$224.63$11,407$389.39+$502.00TQGEX
3$12,972$228.94$12,198$426.53+$774.00TQGEX
4$14,113$233.06$13,056$467.62+$1.1KTQGEX
5$15,338$236.97$13,987$513.12+$1.4KTQGEX
6$16,652$240.69$14,998$563.56+$1.7KTQGEX
7$18,062$244.22$16,098$619.52+$2.0KTQGEX
8$19,574$247.57$17,295$681.69+$2.3KTQGEX
9$21,195$250.74$18,599$750.82+$2.6KTQGEX
10$22,932$253.74$20,022$827.78+$2.9KTQGEX

TQGEX vs JNJ: Complete Analysis 2026

TQGEXStock

The fund invests at least 80% of its net assets (including any borrowings for investment purposes) in equity securities. It invests predominantly in common stocks and may invest in companies of any market capitalization, but will generally focus on large- and mid-cap companies. The fund typically invests in at least five countries, including the U.S., and the amount of the fund’s assets invested outside the U.S. will vary depending on the adviser’s outlook for market conditions and opportunities overseas versus those in the U.S.

Full TQGEX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TQGEX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TQGEX vs SCHDTQGEX vs JEPITQGEX vs OTQGEX vs KOTQGEX vs MAINTQGEX vs ABBVTQGEX vs MRKTQGEX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.